Next Article in Journal
Acute Inflammatory Response in Osteoporotic Fracture Healing Augmented with Mechanical Stimulation is Regulated In Vivo through the p38-MAPK Pathway
Previous Article in Journal
Physalin A, 13,14-Seco-16, 24-Cyclo-Steroid, Inhibits Stemness of Breast Cancer Cells by Regulation of Hedgehog Signaling Pathway and Yes-Associated Protein 1 (YAP1)
Previous Article in Special Issue
Cardiac Protective Effect of Kirenol against Doxorubicin-Induced Cardiac Hypertrophy in H9c2 Cells through Nrf2 Signaling via PI3K/AKT Pathways
Review

The Emerging Role of Epigenetics in Therapeutic Targeting of Cardiomyopathies

by 1,*,† and 1,2,*,†
1
IRCCS-Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Italy
2
Institute of Genetic and Biomedical Research (IRGB), Milan Unit, National Research Council, Via Fantoli 16/15, 20138 Milan, Italy
*
Authors to whom correspondence should be addressed.
These authors contributed equally.
Academic Editors: Chih-Yang Huang, Marthandam Asokan Shibu and Tung-Sheng Chen
Int. J. Mol. Sci. 2021, 22(16), 8721; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22168721
Received: 5 July 2021 / Revised: 6 August 2021 / Accepted: 10 August 2021 / Published: 13 August 2021
(This article belongs to the Special Issue Biomolecular Mediators in Cardiomyopathies)
Cardiomyopathies (CMPs) are a heterogeneous group of myocardial diseases accountable for the majority of cases of heart failure (HF) and/or sudden cardiac death (SCD) worldwide. With the recent advances in genomics, the original classification of CMPs on the basis of morphological and functional criteria (dilated (DCM), hypertrophic (HCM), restrictive (RCM), and arrhythmogenic ventricular cardiomyopathy (AVC)) was further refined into genetic (inherited or familial) and acquired (non-inherited or secondary) forms. Despite substantial progress in the identification of novel CMP-associated genetic variations, as well as improved clinical recognition diagnoses, the functional consequences of these mutations and the exact details of the signaling pathways leading to hypertrophy, dilation, and/or contractile impairment remain elusive. To date, global research has mainly focused on the genetic factors underlying CMP pathogenesis. However, growing evidence shows that alterations in molecular mediators associated with the diagnosis of CMPs are not always correlated with genetic mutations, suggesting that additional mechanisms, such as epigenetics, may play a role in the onset or progression of CMPs. This review summarizes published findings of inherited CMPs with a specific focus on the potential role of epigenetic mechanisms in regulating these cardiac disorders. View Full-Text
Keywords: cardiomyopathies; epigenetics; non coding RNAs (ncRNAs); omics approaches cardiomyopathies; epigenetics; non coding RNAs (ncRNAs); omics approaches
Show Figures

Figure 1

MDPI and ACS Style

Pagiatakis, C.; Di Mauro, V. The Emerging Role of Epigenetics in Therapeutic Targeting of Cardiomyopathies. Int. J. Mol. Sci. 2021, 22, 8721. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22168721

AMA Style

Pagiatakis C, Di Mauro V. The Emerging Role of Epigenetics in Therapeutic Targeting of Cardiomyopathies. International Journal of Molecular Sciences. 2021; 22(16):8721. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22168721

Chicago/Turabian Style

Pagiatakis, Christina, and Vittoria Di Mauro. 2021. "The Emerging Role of Epigenetics in Therapeutic Targeting of Cardiomyopathies" International Journal of Molecular Sciences 22, no. 16: 8721. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22168721

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop